Varsha Babu, MD
Endocrinology · Fresno
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 20 years
- Graduated 2006
Offices
1 location · Central California Faculty Medical Group Inc · 256 clinicians in this group
Hospitals listed: Clovis Community Medical Center · Community Regional Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Babu’s office at (559) 323-9236 to ask if they take your plan before you enroll.
California Medical Board record
Licence A114038 · Current
Licensed to practise in California · since 2010 · expires 2026-09-30 · University of Kerala, T. D. Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Endocrinology, Diabetes and Metabolism
- American Board of Internal Medicine - Internal Medicine
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Clovis Community Medical CenterClovis, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 80% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.7 (12.1 to 17.7) · 421 cases, Jan 2024 – Dec 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.692, Oct 2024 – Sep 2025
- Community Regional Medical CenterFresno, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 1 of 5 starsWorse than the national rate — Death rate among surgical inpatients with serious treatable complications: 211.21 (174.88 to 247.54) · 239 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.705, Oct 2024 – Sep 2025
See every measure and the patient survey for Clovis Community Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 0 better, 6 the same, 1 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.7 (12.1 to 17.7) · 421 cases | Worse | Jan 2024 – Dec 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.692 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.97 (0.04 to 1.89) · 1,840 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.16 (0.86 to 1.45) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 217.06 (167.45 to 266.67) · 84 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 69 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.1 · 165 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.4 · 161 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 14 · 507 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 798 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 336 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 3,771 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.39) · 8,649 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.08 to 0.46) · 9,146 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.46 (1.47 to 5.45) · 1,654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.19 (0.61 to 3.78) · 387 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.18 (0.7 to 3.66) · 1,578 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.47 (7.08 to 19.87) · 374 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.99 (1.37 to 8.61) · 379 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.58 (0.13 to 3.04) · 405 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.8 (0.23 to 1.38) · 8,198 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 90 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.651 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.922 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.449 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.509 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.3 · 210 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 23 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -1.5 · 152 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 58.4 · 556 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18 · 769 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.8 · 802 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (4 to 7.4) · 421 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.2 · 91 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 93 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 200 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.8 to 15.6) · 2,398 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 720 cases | No different | Jan 2024 – Dec 2024 |
What patients said (441 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 80% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Community Regional Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 3 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 211.21 (174.88 to 247.54) · 239 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.705 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.13 (0.29 to 1.96) · 2,304 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.09 (0.87 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 116 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.6 · 445 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.2 · 399 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 582 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 3,744 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.5) · 11,052 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,566 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.33 (1.64 to 5.01) · 3,139 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.08 (0 to 2.3) · 1,423 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.7 (0.52 to 2.88) · 3,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.85 (8.11 to 15.6) · 1,481 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.4 (3.81 to 8.98) · 1,404 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.35 (0.95 to 3.76) · 760 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.64 (0.16 to 1.11) · 10,254 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.817 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.031 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.837 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.81 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.853 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 258 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 689 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 37.4 · 202 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 35.2 · 543 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.2 · 434 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.3 · 552 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.6 to 7.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.3 to 15.4) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.4 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.6 · 248 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.9 (9.5 to 14.9) · 2,590 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 310 cases | No different | Jan 2024 – Dec 2024 |
What patients said (421 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$49,756
Medicare paid this office $49,756 for 355 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 203 | $27,818 | $94 |
| Ultrasound scan of head and neck soft tissue | 105 | $9,273 | $86 |
| Short return visit (20+ min) | 68 | $4,849 | $66 |
| New patient visit (45+ min) | 26 | $3,394 | $131 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 23 | $2,240 | $93 |
See all 7 services
| Return visit (30+ min) | 203 | $27,818 | $94 |
| Ultrasound scan of head and neck soft tissue | 105 | $9,273 | $86 |
| Short return visit (20+ min) | 68 | $4,849 | $66 |
| New patient visit (45+ min) | 26 | $3,394 | $131 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 23 | $2,240 | $93 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 25 | $1,095 | $27 |
| Hemoglobin a1c level | 11 | $105 | $10 |
Who their Medicare patients are
355 Original Medicare patients in 2024. Average age 73 · Under 65 5% · 85 and older 8% · Women 73% · Also on Medicaid 7% · Health risk score 1.24. At or below the middle of the specialty; the typical endocrinology clinician is at 1.46.
Conditions among them: High blood pressure 75% · Diabetes 46% · Coronary heart disease 35% · Chronic kidney disease 35% · Depression 23% · Cancer 18% · Heart failure 13% · COPD 13% · Atrial fibrillation 12% · Stroke 6% · Dementia 3%.
The office billed $117,692, Medicare allowed $68,288 and paid $49,756; for 595 services of 14 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 355 | 595 | 73 | 1.24 | $117,692 | $49,756 |
| 2023 | 354 | 613 | 72 | 1.22 | $115,573 | $50,389 |
| 2022 | 399 | 748 | 73 | 1.22 | $140,138 | $57,159 |
| 2021 | 332 | 742 | 73 | 1.26 | $136,905 | $59,468 |
| 2020 | 355 | 758 | 72 | 1.12 | $147,159 | $54,843 |
| 2019 | 279 | 565 | 72 | 1.24 | $119,181 | $46,602 |
| 2018 | 261 | 411 | 70 | 1.71 | $61,013 | $25,462 |
| 2017 | 322 | 626 | 68 | 1.70 | $69,609 | $31,268 |
| 2016 | 325 | 595 | 68 | 1.73 | $70,320 | $31,910 |
| 2015 | 285 | 576 | 68 | 1.73 | $71,306 | $35,937 |
| 2014 | 241 | 573 | 69 | 1.41 | $64,241 | $30,683 |
| 2013 | 121 | 261 | 70 | 1.20 | $28,125 | $14,951 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Return visit (30+ min) | 216 | $29,924 | $98 |
| Ultrasound scan of head and neck soft tissue | 122 | $10,574 | $85 |
| Short return visit (20+ min) | 60 | $4,288 | $65 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,329 | $106 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 31 | $1,442 | $28 |
| Hemoglobin a1c level | 23 | $257 | $10 |
2022: 7 services
| Return visit (30+ min) | 257 | $34,708 | $89 |
| Ultrasound scan of head and neck soft tissue | 114 | $10,076 | $88 |
| Short return visit (20+ min) | 88 | $5,909 | $59 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,376 | $108 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 34 | $1,507 | $26 |
| New patient visit (45+ min) | 15 | $1,410 | $94 |
| Hemoglobin a1c level | 27 | $268 | $10 |
2021: 8 services
| Return visit (30+ min) | 218 | $35,560 | $95 |
| Ultrasound scan of head and neck soft tissue | 88 | $8,315 | $92 |
| Short return visit (20+ min) | 107 | $7,936 | $65 |
| New patient visit (45+ min) | 19 | $2,195 | $116 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 18 | $1,491 | $43 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,225 | $111 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 20 | $1,123 | $28 |
| Hemoglobin a1c level | 28 | $311 | $10 |
2020: 8 services
| Return visit (30+ min) | 222 | $28,825 | $77 |
| Ultrasound scan of head and neck soft tissue | 90 | $8,149 | $90 |
| Short return visit (20+ min) | 115 | $7,399 | $56 |
| New patient visit (45+ min) | 51 | $5,602 | $110 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 12 | $776 | $41 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 12 | $519 | $29 |
| Short return visit | 11 | $423 | $38 |
| Hemoglobin a1c level | 19 | $241 | $10 |
2019: 5 services
| Return visit (30+ min) | 210 | $27,666 | $82 |
| Ultrasound scan of head and neck soft tissue | 72 | $7,134 | $96 |
| New patient visit (45+ min) | 52 | $6,150 | $118 |
| Short return visit (20+ min) | 36 | $2,322 | $55 |
| Hemoglobin a1c level | 16 | $211 | $11 |
2018: 7 services
| Return visit (30+ min) | 167 | $11,491 | $58 |
| New patient visit (45+ min) | 44 | $5,674 | $129 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $1,821 | $54 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,660 | $104 |
| Ultrasound scan of head and neck soft tissue | 15 | $1,488 | $99 |
| Short return visit (20+ min) | 27 | $802 | $30 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 13 | $489 | $31 |
2017: 7 services
| Return visit (30+ min) | 194 | $15,360 | $54 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $3,994 | $56 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 45 | $3,047 | $30 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,443 | $106 |
| New patient visit (45+ min) | 27 | $2,254 | $83 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 21 | $1,624 | $77 |
| Short return visit (20+ min) | 39 | $1,357 | $33 |
2016: 7 services
| Return visit (30+ min) | 177 | $12,493 | $53 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 49 | $5,683 | $55 |
| New patient visit (45+ min) | 48 | $4,230 | $88 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 40 | $3,054 | $76 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 41 | $2,108 | $30 |
| Short return visit (20+ min) | 36 | $1,357 | $37 |
| Long return visit (40+ min) | 12 | $1,032 | $79 |
2015: 7 services
| Return visit (30+ min) | 149 | $11,633 | $56 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 47 | $6,368 | $59 |
| New patient visit (45+ min) | 61 | $6,114 | $100 |
| Long return visit (40+ min) | 36 | $3,865 | $81 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 29 | $3,047 | $105 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 24 | $1,908 | $80 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 29 | $1,460 | $32 |
2014: 8 services
| Return visit (30+ min) | 109 | $8,297 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 50 | $6,475 | $54 |
| Long return visit (40+ min) | 45 | $3,955 | $72 |
| New patient visit (45+ min) | 35 | $3,257 | $93 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 27 | $2,101 | $78 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 38 | $1,996 | $30 |
| New patient visit (30+ min) | 31 | $1,640 | $53 |
| Insertion of needle into vein for collection of blood sample | 15 | $66 | $3 |
2013: 7 services
| New patient visit (45+ min) | 50 | $4,880 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $2,534 | $54 |
| Return visit (30+ min) | 29 | $1,879 | $59 |
| Long return visit (40+ min) | 15 | $1,223 | $82 |
| New patient visit (30+ min) | 16 | $914 | $57 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 13 | $555 | $29 |
| Insertion of needle into vein for collection of blood sample | 19 | $69 | $3 |
Medicaid work
$105,051 in 2024
Medicaid paid $105,051 for 834 billed services this clinician did in 2024, up to 45 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 287 | $104,454 |
| Short return visit (20+ min) | 119 | $328 |
| Return visit (30+ min) | 374 | $269 |
| Screening for depression is documented as negative, a follow-up plan is not required | 54 | $0 |
| 2024 | 834 | 4 | 45 | $105,051 |
| 2023 | 1,295 | 5 | 50 | $151,678 |
| 2022 | 1,168 | 4 | 53 | $112,055 |
| 2021 | 625 | 3 | 40 | $96,699 |
| 2020 | 331 | 3 | 35 | $63,468 |
| 2019 | 311 | 2 | 42 | $66,231 |
| 2018 | 139 | 2 | 34 | $18,590 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 434 | $151,547 |
| Short return visit (20+ min) | 374 | $94 |
| Return visit (30+ min) | 370 | $37 |
| Glucose, blood by glucose monitoring device(s) cleared by the FDA specifically for home use | 28 | $0 |
| Hemoglobin A1C level | 89 | $0 |
2022
| Clinic visit/encounter, all-inclusive | 380 | $111,975 |
| Short return visit (20+ min) | 418 | $80 |
| Glucose, blood by glucose monitoring device(s) cleared by the FDA specifically for home use | 22 | $0 |
| Return visit (30+ min) | 348 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 327 | $96,699 |
| Short return visit (20+ min) | 154 | $0 |
| Return visit (30+ min) | 144 | $0 |
2020
| Clinic visit/encounter, all-inclusive | 247 | $63,450 |
| Short return visit | 16 | $18 |
| Short return visit (20+ min) | 68 | $0 |
2019
| Clinic visit/encounter, all-inclusive | 293 | $66,231 |
| Short return visit (20+ min) | 18 | $0 |
2018
| Clinic visit/encounter, all-inclusive | 80 | $17,280 |
| Hospital outpatient clinic visit for assessment and management of a patient | 59 | $1,310 |
Drugs they prescribed that Part D paid
$1,723,307
Pharmacies billed $1,723,307 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 3,074) in 2024. At or below the middle of the specialty; the typical endocrinology clinician is at 0%.
1,405 generic and 1,482 brand-name prescriptions · $1,723,307 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ozempic | 273 | $415,671 | $1,523 |
| Signifor Lar | 12 | $223,264 | $18,605 |
| Trulicity | 103 | $172,948 | $1,679 |
| Jardiance | 81 | $121,581 | $1,501 |
| Mounjaro | 86 | $119,782 | $1,393 |
See all 54 drugs
| Ozempic | 273 | $415,671 | $1,523 |
| Signifor Lar | 12 | $223,264 | $18,605 |
| Trulicity | 103 | $172,948 | $1,679 |
| Jardiance | 81 | $121,581 | $1,501 |
| Mounjaro | 86 | $119,782 | $1,393 |
| Teriparatide | 24 | $87,411 | $3,642 |
| Farxiga | 70 | $85,305 | $1,219 |
| Toujeo Max Solostar | 37 | $39,078 | $1,056 |
| Tymlos | 15 | $38,222 | $2,548 |
| Rybelsus | 33 | $36,917 | $1,119 |
| Januvia | 32 | $35,926 | $1,123 |
| Toujeo Solostar | 32 | $21,049 | $658 |
| Kerendia | 13 | $19,814 | $1,524 |
| Tresiba Flextouch U-100 | 28 | $18,346 | $655 |
| Basaglar Kwikpen U-100 | 30 | $16,017 | $534 |
| Synthroid | 129 | $15,917 | $123 |
| Tresiba Flextouch U-200 | 15 | $15,256 | $1,017 |
| Fiasp Flextouch | 13 | $14,402 | $1,108 |
| Lantus Solostar | 63 | $10,964 | $174 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | 17 | $9,710 | $571 |
| Humalog Kwikpen U-100 | 31 | $9,185 | $296 |
| Nano 2nd Gen Pen Needle | 82 | $8,552 | $104 |
| Novolog Flexpen | 37 | $7,909 | $214 |
| Levothyroxine | 455 | $6,627 | $15 |
| Humalog | 23 | $4,935 | $215 |
| Lantus | 17 | $4,483 | $264 |
| Novolog Mix 70-30 Flexpen | 19 | $4,108 | $216 |
| Testosterone | 22 | $3,238 | $147 |
| Ultra-Fine Mini Pen Needle | 29 | $2,379 | $82 |
| Pioglitazone | 102 | $1,868 | $18 |
| Hydrocortisone | 23 | $1,721 | $75 |
| Metformin Hcl Er | 98 | $1,519 | $15 |
| Liothyronine | 37 | $1,435 | $39 |
| Metformin | 134 | $1,124 | $8 |
| Methimazole | 86 | $1,007 | $12 |
| Rosuvastatin | 44 | $954 | $22 |
| Zafemy | 14 | $855 | $61 |
| Calcitriol | 19 | $785 | $41 |
| Raloxifene | 11 | $761 | $69 |
| Testosterone Cypionate | 14 | $706 | $50 |
| Atorvastatin | 48 | $615 | $13 |
| Losartan | 31 | $432 | $14 |
| Omeprazole | 18 | $395 | $22 |
| Ezetimibe | 11 | $327 | $30 |
| Alendronate | 45 | $304 | $7 |
| Glipizide | 25 | $273 | $11 |
| Chlorthalidone | 13 | $272 | $21 |
| Vitamin D2 | 12 | $191 | $16 |
| Spironolactone | 16 | $180 | $11 |
| Norgestimate-Ethinyl Estradiol | 14 | $179 | $13 |
| Lisinopril | 27 | $138 | $5 |
| Glimepiride | 15 | $134 | $9 |
| Amlodipine Besylate | 17 | $103 | $6 |
| Hydrochlorothiazide | 11 | $36 | $3 |
Year by year
| 2024 | 3,074 | 555 | 0% (0) | 48% | $1,723,307 |
| 2023 | 2,866 | 482 | 0% (0) | 47% | $1,832,845 |
| 2022 | 2,718 | 486 | 0% (0) | 51% | $1,541,222 |
| 2021 | 2,314 | 371 | 0% (0) | 50% | $1,224,468 |
| 2020 | 1,999 | 360 | 0% (0) | 47% | $916,187 |
| 2019 | 1,455 | 331 | 0% (0) | 46% | $607,048 |
| 2018 | 2,270 | 287 | 0% (0) | 47% | $856,792 |
| 2017 | 2,320 | 255 | 0% (0) | 54% | $787,636 |
| 2016 | 2,003 | 232 | 0% (0) | 56% | $743,151 |
| 2015 | 1,560 | 192 | None | 60% | $460,714 |
| 2014 | 950 | 139 | 0% (0) | 51% | $230,678 |
| 2013 | 187 | 59 | 0% (0) | None | $29,980 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 51 drugs
| Trulicity | 231 | $391,291 | $1,694 |
| Ozempic | 142 | $236,790 | $1,668 |
| Signifor Lar | 11 | $188,209 | $17,110 |
| Jardiance | 63 | $110,724 | $1,758 |
| Farxiga | 77 | $90,655 | $1,177 |
| Novolog Flexpen | 63 | $79,871 | $1,268 |
| Lantus Solostar | 70 | $63,968 | $914 |
| Forteo | 12 | $53,877 | $4,490 |
| Humalog Kwikpen U-100 | 40 | $51,223 | $1,281 |
| Victoza 3-Pak | 22 | $46,261 | $2,103 |
| Glumetza | 12 | $35,351 | $2,946 |
| Mounjaro | 16 | $28,735 | $1,796 |
| Tresiba Flextouch U-200 | 18 | $24,557 | $1,364 |
| Humalog | 21 | $23,785 | $1,133 |
| Lantus | 17 | $23,758 | $1,398 |
| Toujeo Max Solostar | 19 | $22,835 | $1,202 |
| Basaglar Kwikpen U-100 | 38 | $22,502 | $592 |
| Januvia | 22 | $20,943 | $952 |
| Novolog Mix 70-30 Flexpen | 18 | $17,196 | $955 |
| Humalog Mix 75-25 Kwikpen | 11 | $14,932 | $1,357 |
| Tresiba Flextouch U-100 | 21 | $14,800 | $705 |
| Bydureon Bcise | 11 | $14,772 | $1,343 |
| Synthroid | 93 | $12,582 | $135 |
| Testosterone | 25 | $12,054 | $482 |
| Cinacalcet | 13 | $10,382 | $799 |
| Omnipod 5 G6 Pods (Gen 5) | 13 | $9,966 | $767 |
| Levothyroxine | 399 | $7,723 | $19 |
| Nano 2nd Gen Pen Needle | 58 | $5,700 | $98 |
| Pioglitazone | 122 | $5,013 | $41 |
| Ultra-Fine Mini Pen Needle | 47 | $4,206 | $89 |
| Hydrocortisone | 57 | $3,452 | $61 |
| Metformin | 136 | $2,780 | $20 |
| Liothyronine | 35 | $1,941 | $55 |
| Metformin Hcl Er | 99 | $1,709 | $17 |
| Rosuvastatin | 41 | $1,466 | $36 |
| Calcitriol | 16 | $1,322 | $83 |
| Methimazole | 68 | $1,068 | $16 |
| Atorvastatin | 52 | $929 | $18 |
| Cabergoline | 11 | $864 | $79 |
| Spironolactone | 14 | $852 | $61 |
| Losartan | 24 | $695 | $29 |
| Testosterone Cypionate | 11 | $617 | $56 |
| Alendronate | 42 | $598 | $14 |
| Omeprazole | 17 | $563 | $33 |
| Lisinopril | 28 | $409 | $15 |
| Glipizide Er | 13 | $402 | $31 |
| Glimepiride | 13 | $380 | $29 |
| Amlodipine Besylate | 17 | $265 | $16 |
| Glipizide | 25 | $186 | $7 |
| Metoprolol | 11 | $155 | $14 |
| Hydrochlorothiazide | 27 | $93 | $3 |
2022: 53 drugs
| Trulicity | 215 | $369,424 | $1,718 |
| Ozempic | 103 | $164,110 | $1,593 |
| Novolog Flexpen | 82 | $105,713 | $1,289 |
| Jardiance | 73 | $103,014 | $1,411 |
| Lantus Solostar | 85 | $75,828 | $892 |
| Farxiga | 64 | $71,000 | $1,109 |
| Victoza 3-Pak | 21 | $52,044 | $2,478 |
| Humalog Kwikpen U-100 | 32 | $41,007 | $1,281 |
| Tymlos | 17 | $40,827 | $2,402 |
| Glumetza | 13 | $38,531 | $2,964 |
| Basaglar Kwikpen U-100 | 46 | $26,370 | $573 |
| Novolog | 14 | $23,319 | $1,666 |
| Novolog Mix 70-30 Flexpen | 26 | $22,934 | $882 |
| Bydureon Bcise | 18 | $22,578 | $1,254 |
| Januvia | 21 | $21,869 | $1,041 |
| Lantus | 14 | $21,444 | $1,532 |
| Tresiba Flextouch U-200 | 18 | $21,088 | $1,172 |
| Levemir Flextouch | 16 | $19,716 | $1,232 |
| Tradjenta | 12 | $18,938 | $1,578 |
| Rybelsus | 14 | $16,052 | $1,147 |
| Toujeo Max Solostar | 14 | $13,708 | $979 |
| Synthroid | 114 | $13,677 | $120 |
| Humalog | 13 | $13,454 | $1,035 |
| Testosterone | 31 | $11,906 | $384 |
| Levothyroxine | 394 | $8,310 | $21 |
| Nano 2nd Gen Pen Needle | 36 | $3,397 | $94 |
| Ultra-Fine Mini Pen Needle | 33 | $2,914 | $88 |
| Liothyronine | 48 | $2,905 | $61 |
| Cabergoline | 11 | $1,849 | $168 |
| Rosuvastatin | 47 | $1,573 | $33 |
| Metformin | 130 | $1,572 | $12 |
| Hydrocortisone | 34 | $1,542 | $45 |
| Calcitriol | 21 | $1,370 | $65 |
| Pioglitazone | 58 | $1,194 | $21 |
| Methimazole | 72 | $950 | $13 |
| Metformin Hcl Er | 93 | $900 | $10 |
| Testosterone Cypionate | 17 | $839 | $49 |
| Novolin 70-30 | 14 | $821 | $59 |
| Spironolactone | 14 | $665 | $48 |
| Atorvastatin | 60 | $641 | $11 |
| Veo Insulin | 12 | $460 | $38 |
| Prednisone | 13 | $453 | $35 |
| Glipizide Er | 22 | $383 | $17 |
| Glimepiride | 14 | $355 | $25 |
| Losartan | 17 | $245 | $14 |
| Glipizide | 31 | $241 | $8 |
| Pravastatin | 15 | $220 | $15 |
| Omeprazole | 16 | $215 | $13 |
| Euthyrox | 13 | $212 | $16 |
| Alendronate | 25 | $164 | $7 |
| Lisinopril | 18 | $124 | $7 |
| Hydrochlorothiazide | 29 | $97 | $3 |
| Amlodipine Besylate | 18 | $68 | $4 |
2021: 53 drugs
| Trulicity | 144 | $255,878 | $1,777 |
| Lantus Solostar | 86 | $82,193 | $956 |
| Novolog Flexpen | 65 | $81,985 | $1,261 |
| Humalog Kwikpen U-100 | 56 | $81,570 | $1,457 |
| Forteo | 20 | $78,576 | $3,929 |
| Jardiance | 52 | $68,402 | $1,315 |
| Victoza 3-Pak | 30 | $60,860 | $2,029 |
| Ozempic | 33 | $49,984 | $1,515 |
| Farxiga | 39 | $48,201 | $1,236 |
| Glumetza | 13 | $39,033 | $3,003 |
| Novolog Mix 70-30 Flexpen | 18 | $26,803 | $1,489 |
| Januvia | 23 | $26,444 | $1,150 |
| Tradjenta | 18 | $24,364 | $1,354 |
| Lantus | 16 | $22,329 | $1,396 |
| Toujeo Solostar | 17 | $20,966 | $1,233 |
| Tresiba Flextouch U-200 | 11 | $18,575 | $1,689 |
| Basaglar Kwikpen U-100 | 43 | $17,829 | $415 |
| Levemir Flextouch | 17 | $17,397 | $1,023 |
| Humalog | 13 | $16,760 | $1,289 |
| Synthroid | 125 | $12,959 | $104 |
| Levothyroxine | 362 | $9,266 | $26 |
| Tresiba Flextouch U-100 | 11 | $5,696 | $518 |
| Liothyronine | 47 | $3,029 | $64 |
| Ultra-Fine Mini Pen Needle | 25 | $2,882 | $115 |
| Testosterone | 19 | $2,826 | $149 |
| Nano 2nd Gen Pen Needle | 21 | $2,025 | $96 |
| Novolin 70-30 | 19 | $1,719 | $90 |
| Calcitriol | 19 | $1,452 | $76 |
| Hydrocortisone | 12 | $1,248 | $104 |
| Metformin | 104 | $1,118 | $11 |
| Rosuvastatin | 26 | $1,093 | $42 |
| Testosterone Cypionate | 20 | $1,028 | $51 |
| Pioglitazone | 37 | $899 | $24 |
| Atorvastatin | 48 | $800 | $17 |
| Duloxetine | 16 | $713 | $45 |
| Methimazole | 48 | $710 | $15 |
| Metformin Hcl Er | 52 | $684 | $13 |
| Glimepiride | 16 | $556 | $35 |
| Glipizide Er | 24 | $536 | $22 |
| Veo Insulin | 11 | $363 | $33 |
| Ibandronate | 11 | $321 | $29 |
| Omeprazole | 18 | $288 | $16 |
| Pravastatin | 14 | $278 | $20 |
| Lisinopril | 21 | $263 | $13 |
| Spironolactone | 17 | $251 | $15 |
| Norgestimate-Ethinyl Estradiol | 17 | $240 | $14 |
| Losartan | 16 | $214 | $13 |
| Euthyrox | 15 | $178 | $12 |
| Glipizide | 28 | $169 | $6 |
| Amlodipine Besylate | 20 | $160 | $8 |
| Hydrochlorothiazide | 27 | $142 | $5 |
| Alendronate | 15 | $139 | $9 |
| Simvastatin | 11 | $47 | $4 |
2020: 46 drugs
| Trulicity | 149 | $190,186 | $1,276 |
| Victoza 3-Pak | 38 | $78,161 | $2,057 |
| Forteo | 21 | $77,942 | $3,712 |
| Humalog Kwikpen U-100 | 46 | $65,783 | $1,430 |
| Lantus Solostar | 64 | $48,463 | $757 |
| Novolog Flexpen | 56 | $46,855 | $837 |
| Glumetza | 11 | $29,790 | $2,708 |
| Jardiance | 23 | $29,078 | $1,264 |
| Toujeo Solostar | 19 | $26,418 | $1,390 |
| Lantus | 18 | $23,958 | $1,331 |
| Januvia | 32 | $23,228 | $726 |
| Bydureon | 15 | $12,701 | $847 |
| Testosterone | 12 | $9,743 | $812 |
| Synthroid | 98 | $9,585 | $98 |
| Levothyroxine | 322 | $9,557 | $30 |
| Tirosint | 22 | $4,166 | $189 |
| Ultra-Fine Nano Pen Needle | 23 | $2,093 | $91 |
| Liothyronine | 34 | $1,743 | $51 |
| Ultra-Fine Mini Pen Needle | 16 | $1,678 | $105 |
| Calcitriol | 14 | $1,624 | $116 |
| Atorvastatin | 54 | $1,129 | $21 |
| Ultra-Fine Micro Pen Needle | 12 | $1,042 | $87 |
| Metformin | 98 | $969 | $10 |
| Methimazole | 49 | $869 | $18 |
| Pioglitazone | 33 | $813 | $25 |
| Rosuvastatin | 13 | $797 | $61 |
| Hydrocortisone | 17 | $741 | $44 |
| Duloxetine | 21 | $571 | $27 |
| Metformin Hcl Er | 40 | $492 | $12 |
| Gabapentin | 13 | $418 | $32 |
| Novolin 70-30 | 11 | $373 | $34 |
| Losartan | 22 | $348 | $16 |
| Insulin | 11 | $318 | $29 |
| Pravastatin | 15 | $316 | $21 |
| Ibandronate | 11 | $298 | $27 |
| Glipizide Er | 11 | $255 | $23 |
| Alendronate | 21 | $175 | $8 |
| Simvastatin | 18 | $169 | $9 |
| Norgestimate-Ethinyl Estradiol | 13 | $158 | $12 |
| Pantoprazole | 11 | $158 | $14 |
| Amlodipine Besylate | 22 | $142 | $6 |
| Lisinopril | 23 | $122 | $5 |
| Glipizide | 20 | $121 | $6 |
| Hydrochlorothiazide | 14 | $116 | $8 |
| Spironolactone | 12 | $99 | $8 |
| Dexamethasone | 11 | $14 | $1 |
2019: 34 drugs
| Trulicity | 119 | $112,839 | $948 |
| Victoza 3-Pak | 46 | $75,470 | $1,641 |
| Novolog Flexpen | 56 | $55,213 | $986 |
| Forteo | 11 | $39,268 | $3,570 |
| Humalog Kwikpen U-100 | 27 | $30,714 | $1,138 |
| Lantus Solostar | 38 | $25,501 | $671 |
| Toujeo Solostar | 12 | $22,302 | $1,859 |
| Jardiance | 22 | $19,656 | $893 |
| Basaglar Kwikpen U-100 | 24 | $12,429 | $518 |
| Tresiba Flextouch U-200 | 11 | $12,402 | $1,127 |
| Humalog | 12 | $11,996 | $1,000 |
| Januvia | 15 | $10,921 | $728 |
| Levemir Flextouch | 11 | $7,746 | $704 |
| Levothyroxine | 188 | $5,012 | $27 |
| Synthroid | 46 | $4,327 | $94 |
| Ultra-Fine Nano Pen Needle | 22 | $1,697 | $77 |
| Liothyronine | 30 | $1,672 | $56 |
| Duloxetine | 30 | $1,603 | $53 |
| Hydrocortisone | 28 | $1,499 | $54 |
| Rosuvastatin | 12 | $998 | $83 |
| Atorvastatin | 47 | $754 | $16 |
| Metformin Hcl Er | 54 | $671 | $12 |
| Metformin | 59 | $637 | $11 |
| Pioglitazone | 26 | $428 | $16 |
| Pravastatin | 25 | $421 | $17 |
| Glipizide Er | 13 | $315 | $24 |
| Alendronate | 33 | $294 | $9 |
| Insulin | 11 | $271 | $25 |
| Methimazole | 18 | $243 | $13 |
| Spironolactone | 11 | $150 | $14 |
| Omeprazole | 14 | $145 | $10 |
| Lisinopril | 25 | $133 | $5 |
| Hydrochlorothiazide | 23 | $71 | $3 |
| Amlodipine Besylate | 11 | $70 | $6 |
2018: 44 drugs
| Victoza 3-Pak | 93 | $142,132 | $1,528 |
| Novolog Flexpen | 149 | $135,566 | $910 |
| Forteo | 30 | $101,458 | $3,382 |
| Tresiba Flextouch U-200 | 82 | $93,708 | $1,143 |
| Trulicity | 31 | $37,079 | $1,196 |
| Humalog Kwikpen U-100 | 29 | $27,950 | $964 |
| Lantus Solostar | 47 | $23,576 | $502 |
| Novolog | 23 | $21,922 | $953 |
| Toujeo Solostar | 19 | $14,013 | $738 |
| Basaglar Kwikpen U-100 | 34 | $13,826 | $407 |
| Levemir Flextouch | 24 | $13,035 | $543 |
| Januvia | 11 | $12,628 | $1,148 |
| Levemir | 11 | $11,151 | $1,014 |
| Humalog | 12 | $11,104 | $925 |
| Tresiba Flextouch U-100 | 27 | $10,030 | $371 |
| Victoza 2-Pak | 11 | $9,506 | $864 |
| Levothyroxine | 326 | $9,029 | $28 |
| Synthroid | 107 | $7,891 | $74 |
| Hydrocortisone | 62 | $3,965 | $64 |
| Liothyronine | 49 | $2,142 | $44 |
| Duloxetine | 31 | $1,962 | $63 |
| Ultra-Fine Short Pen Needle | 21 | $1,901 | $91 |
| Rosuvastatin | 33 | $1,700 | $52 |
| Pravastatin | 84 | $1,509 | $18 |
| Ultra-Fine Mini Pen Needle | 20 | $894 | $45 |
| Ulticare Pen Needle | 17 | $857 | $50 |
| Metformin | 99 | $826 | $8 |
| Divalproex Sodium Er | 20 | $810 | $41 |
| Metformin Hcl Er | 73 | $663 | $9 |
| Atorvastatin | 41 | $659 | $16 |
| Glipizide Er | 21 | $593 | $28 |
| Unifine Pentips | 22 | $580 | $26 |
| Trueplus Pen Needle | 20 | $578 | $29 |
| Spironolactone | 14 | $576 | $41 |
| Fludrocortisone Acetate | 16 | $355 | $22 |
| Alendronate | 35 | $280 | $8 |
| Losartan | 31 | $240 | $8 |
| Lisinopril | 44 | $211 | $5 |
| Furosemide | 23 | $206 | $9 |
| Methotrexate | 14 | $204 | $15 |
| Methimazole | 17 | $196 | $12 |
| Simvastatin | 23 | $131 | $6 |
| Amlodipine Besylate | 28 | $130 | $5 |
| Hydrochlorothiazide | 30 | $99 | $3 |
2017: 42 drugs
| Victoza 3-Pak | 106 | $136,304 | $1,286 |
| Novolog Flexpen | 160 | $133,584 | $835 |
| Forteo | 27 | $93,656 | $3,469 |
| Lantus Solostar | 118 | $50,896 | $431 |
| Tresiba Flextouch U-200 | 45 | $45,202 | $1,004 |
| Levemir Flextouch | 55 | $31,841 | $579 |
| Humalog Kwikpen U-100 | 33 | $30,489 | $924 |
| Januvia | 63 | $25,231 | $400 |
| Humalog | 31 | $20,868 | $673 |
| Novolog | 24 | $20,071 | $836 |
| Levemir | 22 | $17,872 | $812 |
| Trulicity | 18 | $16,141 | $897 |
| Victoza 2-Pak | 21 | $12,261 | $584 |
| Sensipar | 11 | $10,638 | $967 |
| Levothyroxine | 378 | $10,417 | $28 |
| Tresiba Flextouch U-100 | 37 | $9,723 | $263 |
| Synthroid | 99 | $5,422 | $55 |
| Glucagon Emergency Kit | 14 | $3,755 | $268 |
| Hydrocortisone | 49 | $3,411 | $70 |
| Ultra-Fine Short Pen Needle | 34 | $3,206 | $94 |
| Lyrica | 13 | $2,863 | $220 |
| Novolin N | 14 | $1,944 | $139 |
| Novolin R | 14 | $1,762 | $126 |
| Liothyronine | 44 | $1,707 | $39 |
| Novofine | 18 | $1,405 | $78 |
| Duloxetine | 16 | $1,148 | $72 |
| Rosuvastatin | 15 | $1,034 | $69 |
| Pravastatin | 68 | $873 | $13 |
| Autoshield Duo Pen Needle | 13 | $800 | $62 |
| Ultra-Fine Mini Pen Needle | 18 | $797 | $44 |
| Unifine Pentips | 21 | $739 | $35 |
| Atorvastatin | 53 | $725 | $14 |
| Metformin | 81 | $679 | $8 |
| Metformin Hcl Er | 63 | $481 | $8 |
| Alendronate | 20 | $417 | $21 |
| Methimazole | 28 | $324 | $12 |
| Losartan | 20 | $265 | $13 |
| Lisinopril | 49 | $261 | $5 |
| Amlodipine Besylate | 26 | $186 | $7 |
| Hydrochlorothiazide | 18 | $100 | $6 |
| Furosemide | 20 | $96 | $5 |
| Simvastatin | 27 | $96 | $4 |
2016: 37 drugs
| Novolog Flexpen | 160 | $133,529 | $835 |
| Victoza 3-Pak | 133 | $128,954 | $970 |
| Forteo | 21 | $83,589 | $3,980 |
| Lantus Solostar | 131 | $62,581 | $478 |
| Levemir Flextouch | 79 | $43,501 | $551 |
| Humalog | 44 | $36,430 | $828 |
| Humalog Kwikpen U-100 | 39 | $31,815 | $816 |
| Toujeo Solostar | 24 | $27,486 | $1,145 |
| Januvia | 48 | $21,425 | $446 |
| Novolog | 38 | $20,082 | $528 |
| Lantus | 19 | $14,442 | $760 |
| Levemir | 16 | $13,943 | $871 |
| Tresiba Flextouch U-200 | 13 | $11,975 | $921 |
| Trulicity | 16 | $10,484 | $655 |
| Levothyroxine | 313 | $8,023 | $26 |
| Tresiba Flextouch U-100 | 14 | $5,666 | $405 |
| Lyrica | 11 | $5,594 | $509 |
| Bd Ultra-Fine Pen Needle | 32 | $2,974 | $93 |
| Synthroid | 65 | $2,464 | $38 |
| Hydrocortisone | 42 | $2,353 | $56 |
| Novofine | 23 | $1,362 | $59 |
| Atorvastatin | 66 | $962 | $15 |
| Liothyronine | 19 | $629 | $33 |
| Metformin | 71 | $580 | $8 |
| Pravastatin | 64 | $558 | $9 |
| Metformin Hcl Er | 58 | $548 | $9 |
| Unifine Pentips | 11 | $367 | $33 |
| Lisinopril | 39 | $353 | $9 |
| Glipizide Er | 14 | $344 | $25 |
| Prednisone | 21 | $301 | $14 |
| Methimazole | 20 | $206 | $10 |
| Simvastatin | 16 | $140 | $9 |
| Glipizide | 11 | $112 | $10 |
| Amlodipine Besylate | 16 | $78 | $5 |
| Furosemide | 14 | $76 | $5 |
| Hydrochlorothiazide | 11 | $73 | $7 |
| Alprazolam | 20 | $20 | $1 |
2015: 26 drugs
| Novolog Flexpen | 123 | $88,364 | $718 |
| Victoza 3-Pak | 106 | $82,533 | $779 |
| Levemir Flextouch | 91 | $47,673 | $524 |
| Lantus Solostar | 94 | $42,813 | $455 |
| Humalog Kwikpen U-100 | 34 | $20,579 | $605 |
| Novolog | 45 | $19,371 | $430 |
| Lantus | 51 | $19,124 | $375 |
| Victoza 2-Pak | 24 | $16,756 | $698 |
| Humalog | 34 | $15,699 | $462 |
| Crestor | 42 | $11,823 | $282 |
| Levothyroxine | 179 | $5,297 | $30 |
| Invokana | 11 | $4,898 | $445 |
| Farxiga | 13 | $3,840 | $295 |
| Hydrocortisone | 38 | $2,959 | $78 |
| Bd Ultra-Fine Pen Needle | 38 | $2,785 | $73 |
| Synthroid | 59 | $1,851 | $31 |
| Metformin | 84 | $854 | $10 |
| Atorvastatin | 60 | $829 | $14 |
| Insulin | 21 | $625 | $30 |
| Metformin Hcl Er | 49 | $523 | $11 |
| Lisinopril | 29 | $238 | $8 |
| Simvastatin | 13 | $151 | $12 |
| Glipizide | 17 | $147 | $9 |
| Amlodipine Besylate | 13 | $93 | $7 |
| Losartan | 13 | $71 | $5 |
| Furosemide | 12 | $39 | $3 |
2014: 24 drugs
| Novolog Flexpen | 66 | $42,205 | $639 |
| Lantus Solostar | 79 | $37,128 | $470 |
| Humalog | 59 | $34,393 | $583 |
| Victoza 3-Pak | 37 | $24,899 | $673 |
| Levemir Flexpen | 29 | $13,375 | $461 |
| Levemir Flextouch | 27 | $11,713 | $434 |
| Novolog | 32 | $10,075 | $315 |
| Januvia | 16 | $8,697 | $544 |
| Lantus | 24 | $8,541 | $356 |
| Crestor | 16 | $4,957 | $310 |
| Bd Ultra-Fine Pen Needle | 50 | $3,385 | $68 |
| Levothyroxine | 99 | $3,080 | $31 |
| Hydrocortisone | 21 | $1,065 | $51 |
| Synthroid | 17 | $847 | $50 |
| Metformin | 60 | $834 | $14 |
| Lisinopril | 30 | $296 | $10 |
| Atorvastatin | 14 | $286 | $20 |
| Metformin Hcl Er | 15 | $243 | $16 |
| Unifine Pentips | 11 | $178 | $16 |
| Glipizide Er | 11 | $175 | $16 |
| Losartan | 16 | $147 | $9 |
| Simvastatin | 12 | $105 | $9 |
| Furosemide | 16 | $83 | $5 |
| Carvedilol | 11 | $60 | $5 |
2013: 3 drugs
| Januvia | 12 | $3,237 | $270 |
| Metformin | 15 | $212 | $14 |
| Lisinopril | 13 | $104 | $8 |
Money from drug and device companies
$298 in 2025
| 2025 | 3 | 3 | None | $298 |
| 2024 | 7 | 12 | None | $285 |
| 2023 | 28 | 114 | None | $2,242 |
| 2022 | 28 | 90 | None | $2,265 |
| 2021 | 20 | 47 | None | $1,050 |
| 2020 | 10 | 21 | None | $518 |
| 2019 | 3 | 11 | None | $458 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Neurocrine BioSciences | Crenessity | $103 | 1 payment
|
| Amgen | Tavneos | $98 | 1 payment
|
| Dexcom | Dexcom G7 Gss (161) | $98 | 1 payment
|
See all 3 published payments
| Amgen | Meals · 2025-07-14 | Tavneos | $98 |
| Neurocrine BioSciences | Meals · 2025-05-27 | Crenessity | $103 |
| Dexcom | Meals · 2025-03-16 | Dexcom G7 Gss (161) | $98 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $285
| Radius Health | Tymlos | $79 | 2 payments
|
| Lilly USA | Jardiance | $57 | 3 payments
|
| Medtronic | Minimed 780g | $45 | 2 payments
|
| Xeris Pharmaceuticals | Gvoke Hypopen | $39 | 2 payments
|
| Ascensia Diabetes Care Us | Eversense E3 Sensor Kit - Retail | $24 | 1 payment
|
| Abbott Laboratories | Freestyle Libre 3 | $22 | 1 payment
|
| Novo Nordisk | Ozempic | $19 | 1 payment
|
2023: $2,242
| Dexcom | Dexcom G6 Transmitter | $268 | 10 payments
|
| Novo Nordisk | Rybelsus | $225 | 12 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $209 | 7 payments
|
| Lilly USA | Baqsimi | $191 | 17 payments
|
| Recordati Rare Diseases Inc. | Signifor Lar | $147 | 3 payments
|
| Abbott Laboratories | Freestyle Libre 3 | $141 | 15 payments
|
| Boehringer Ingelheim Pharmaceuticals | Tradjenta | $128 | 6 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $120 | 5 payments
|
| Amgen | Evenity | $110 | 5 payments
|
| Xeris Pharmaceuticals | Gvoke Hypopen | $91 | 5 payments
|
| MannKind | Afrezza | $76 | 4 payments
|
| Ascensia Diabetes Care Us | None | $66 | 3 payments
|
| Nevro | Senza | $65 | 2 payments
|
| Horizon Therapeutics plc | Tepezza | $53 | 3 payments
|
| Insulet | Omnipod | $50 | 2 payments
|
| Tandem Diabetes Care | T:Slim X2 Insulin Pump With Control-Iq | $46 | 2 payments
|
| Antares Pharma | Nocdurna | $40 | 2 payments
|
| Ascendis Pharma | None | $26 | 1 payment
|
| Pfizer | Genotropin | $24 | 1 payment
|
| Alexion Pharmaceuticals | Strensiq | $22 | 1 payment
|
| Supernus Pharmaceuticals | Xyosted | $21 | 1 payment
|
| Medtronic | Minimed 780g | $19 | 1 payment
|
| Sanofi-Aventis U.S. | Tzield | $19 | 1 payment
|
| Radius Health | None | $18 | 1 payment
|
| Kyowa Kirin | Crysvita | $18 | 1 payment
|
| Esperion Therapeutics | Nexletol | $18 | 1 payment
|
| Acella Pharmaceuticals | NP Thyroid 60 | $16 | 1 payment
|
| Amryt Pharma Holdings | Mycapssa | $15 | 1 payment
|
2022: $2,265
| Lilly USA | Mounjaro | $280 | 17 payments
|
| Dexcom | Dexcom G6 Transmitter | $225 | 10 payments
|
| Amgen | Evenity | $176 | 4 payments
|
| Radius Health | Tymlos | $152 | 2 payments
|
| Boston Scientific | Wavewriter Alpha Prime 16 | $139 | 1 payment
|
| Abbott Laboratories | Freestyle Libre 2 | $135 | 5 payments
|
| Antares Pharma | Xyosted | $125 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $109 | 6 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $105 | 5 payments
|
| Corcept Therapeutics | Korlym | $101 | 4 payments
|
| Mannkind | Afrezza | $74 | 3 payments
|
| EUSA Pharma (US) | Sylvant | $65 | 3 payments
|
| Recordati Rare Diseases Inc. | Isturisa | $65 | 3 payments
|
| Medtronic | Minimed 770g | $59 | 4 payments
|
| Novo Nordisk | Ozempic | $50 | 3 payments
|
| Nevro | Omnia | $45 | 1 payment
|
| Alexion Pharmaceuticals | Strensiq | $44 | 2 payments
|
| Amryt Pharma Holdings | Mycapssa | $43 | 2 payments
|
| Insulet | Omnipod | $43 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $41 | 2 payments
|
| IBSA Pharma | Tirosint | $39 | 2 payments
|
| Sanofi-Aventis U.S. | Toujeo | $34 | 2 payments
|
| Amarin Pharma | Vascepa | $24 | 1 payment
|
| Zealand Pharma US | Zegalogue | $23 | 1 payment
|
| Lifescan | Onetouch Verio Reflect | $22 | 1 payment
|
| Ultragenyx Pharmaceutical | Crysvita | $18 | 1 payment
|
| Xeris Pharmaceuticals | Gvoke Pfs | $14 | 1 payment
|
| Bigfoot Biomedical | Unity Diabetes Management System | $12 | 1 payment
|
2021: $1,050
| Novo Nordisk | Wegovy | $169 | 4 payments
|
| Abbott Laboratories | Freestyle Libre | $126 | 10 payments
|
| Tandem Diabetes Care | T-Slim Insulin Pump | $121 | 1 payment
|
| MannKind | Afrezza | $100 | 3 payments
|
| Insulet | Omnipod | $72 | 5 payments
|
| Corcept Therapeutics | Korlym | $70 | 3 payments
|
| Medtronic | Minimed 670g System | $68 | 4 payments
|
| Ipsen Biopharmaceuticals | Somatuline Depot | $67 | 3 payments
|
| Dexcom | Dexcom G6 Transmitter | $56 | 3 payments
|
| Horizon Therapeutics plc | Tepezza | $23 | 1 payment
|
| Xeris Pharmaceuticals | Gvoke Pfs | $22 | 1 payment
|
| Pfizer | Somavert | $20 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $19 | 1 payment
|
| LifeScan | Onetouch Verio Reflect | $19 | 1 payment
|
| Sanofi-Aventis U.S. | Soliqua 100/33 | $18 | 1 payment
|
| Alexion Pharmaceuticals | Strensiq | $17 | 1 payment
|
| Ascensia Diabetes Care US | None | $16 | 1 payment
|
| Ultragenyx Pharmaceutical | Crysvita | $16 | 1 payment
|
| Esperion Therapeutics | Nexletol | $16 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Tradjenta | $15 | 1 payment
|
2020: $518
| Tandem Diabetes Care | T:Slim X2 Insulin Pump | $125 | 1 payment
|
| Amgen | Corlanor | $97 | 4 payments
|
| Corcept Therapeutics | Korlym | $61 | 2 payments
|
| Insulet | Omnipod | $61 | 3 payments
|
| Medtronic MiniMed | Minimed 670g System | $45 | 3 payments
|
| Sanofi-Aventis U.S. | Soliqua 100/33 | $32 | 2 payments
|
| Eisai | Lenvima | $32 | 2 payments
|
| Novo Nordisk | Ozempic | $27 | 2 payments
|
| Dexcom | Dexcom G6 Cgm System | $21 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $18 | 1 payment
|
2019: $458
| Amgen | Repatha | $221 | 9 payments
|
| AbbVie | Synthroid | $120 | 1 payment
|
| Novo Nordisk | Ozempic | $118 | 1 payment
|
Professional record
- NPI
- 1972755452
- Licence
- CA A114038California A114038: Current · expires 2026-09-30
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RE0101X (207RE0101X); Internal medicine (207R00000X)
- Mailing address
- 2625 E Divisadero St, Fresno, CA, 93721
- NPI first listed
- 2008-10-16
- NPI last updated
- 2024-12-23
- NPI record certified
- 2024-12-23
This is when the NPI record was last certified, not a medical board exam.